Three cycles versus six cycles of adjuvant paclitaxel (Taxol)/carboplatin in early stage ovarian cancer.

abstract：:Phase I studies of CPT-11 (irinotecan) have been conducted in Europe, the United States, and Japan to determine the maximum tolerated dose (MTD) and the most appropriate intravenous administration schedule for further evaluation in phase II investigations. Diarrhea and/or neutropenia were the major dose-limiting toxic...

journal_title：Seminars in oncology

authors： Armand JP

更新日期：1996-02-01 00:00:00

abstract：:Session IV of the Second International Colloquium on Cardio-Oncology held in Kraków, focused on the cardiovascular risks of using hormone replacement therapy in breast cancer and androgen deprivation therapy in prostate cancer and continued the theme from Session 3 with a discussion of risk reduction strategies. The d...

journal_title：Seminars in oncology

authors： Plummer C,Steingart RM,Jurczak W,Iakobishvili Z,Lyon AR,Plastaras JP,Minotti G

更新日期：2019-12-01 00:00:00

abstract：:Pharmacologic interventions for cancer risk reduction involve the chronic administration of synthetic or natural agents to reduce or delay the occurrence of malignancy. Despite the strong evidence for a favorable risk-benefit ratio for a number of agents in several common malignancies such as breast and prostate cance...

journal_title：Seminars in oncology

authors： Lazzeroni M,DeCensi A

更新日期：2016-02-01 00:00:00

abstract：:Among the various deleterious effects of cancer chemotherapy, vascular toxicity is the least well recognized. This lack of recognition may be because the vasculotoxic phenomena are not unique to antineoplastic agents, can occur in patients without exposure to these agents, and the fact cancer itself may produce a hype...

journal_title：Seminars in oncology

authors： Shahab N,Haider S,Doll DC

更新日期：2006-02-01 00:00:00

abstract：:The majority of patients with advanced prostatic cancer respond either to castration or estrogen therapy. In an attempt to identify an alternative hormonal therapy, 25 symptomatic stage D prostate cancer patients were treated with megestrol acetate as initial hormonal therapy. Thirty-three patients were evaluable for ...

journal_title：Seminars in oncology

authors： Bonomi P,Pessis D,Bunting N,Block M,Anderson K,Wolter J,Rossof A,Slayton R,Harris J

更新日期：1985-03-01 00:00:00

abstract：:Traditional cancer diagnostic techniques include assessment of histologic appearance, identification of specific tumor subtypes, tumor grading, assessment of lymph node status, and presence of metastasis. These are useful for initial evaluation, but are limited in their ability to predict response to treatment and/or ...

journal_title：Seminars in oncology

authors： Perez EA,Pusztai L,Van de Vijver M

更新日期：2004-10-01 00:00:00

abstract：:Aberrant activation of the three-layered protein kinase cascade, Raf/MEK/ERK, is often detected in human cancer, which is mainly attributed to the oncogenic alterations of RAF, or its upstream activators RAS or cell surface receptor tyrosine kinases. Deregulated activity of the Raf/MEK/ERK pathway drives uncontrolled ...

journal_title：Seminars in oncology

authors： Wu PK,Park JI

更新日期：2015-12-01 00:00:00

abstract：:Current data indicate that most elderly patients with acute myelogenous leukemia should be treated with intensive chemotherapy. Most should receive remission induction chemotherapy using cytarabine 100 to 200 mg/m2/d by constant intravenous infusion for five to seven days plus daunorubicin greater than or equal to 30 ...

journal_title：Seminars in oncology

authors： Champlin RE,Gajewski JL,Golde DW

更新日期：1989-02-01 00:00:00

abstract：:Imaging prostate cancer continues to represent a clinical challenge for both primary and recurrent disease. In the evaluation of the persistent/recurrent/metastatic prostate cancer, knowledge of cancer location (local v distant), size, and extent are essential in order to design a treatment, tailored to each patient's...

journal_title：Seminars in oncology

authors： Hricak H,Schöder H,Pucar D,Lis E,Eberhardt SC,Onyebuchi CN,Scher HI

更新日期：2003-10-01 00:00:00

abstract：:This ongoing study was initiated to determine the feasibility of administering amifostine (Ethyol, WR-2721; MedImmune, Inc, Gaithersburg, MD) with monomodal high-dose rate (mHDR) brachytherapy and to assess the tolerability and side effects of this combination. To date, 18 patients suitable for prostate implant brachy...

journal_title：Seminars in oncology

authors： Dziuk T,Senzer N

更新日期：2003-12-01 00:00:00

abstract：:With the increasing numbers of breast cancers survivors, menopause, its symptoms, and its physical complications are becoming more prevalent problems in this patient population. Hormonal replacement, which has been the cornerstone therapy of menopausal related symptoms for decades, recently has been shown to increase ...

journal_title：Seminars in oncology

authors： Bruno D,Feeney KJ

更新日期：2006-12-01 00:00:00

abstract：:Cisplatin is recognized as an active chemotherapeutic agent in a broad variety of human tumors. The severe emetic effects of cisplatin, however, result in both acute and delayed emesis syndromes causing considerable morbidity. Over the last decade, the standard of therapy for control of cisplatin-induced emesis has be...

journal_title：Seminars in oncology

authors： Perez EA,Hesketh PJ,Gandara DR

更新日期：1991-02-01 00:00:00

abstract：:Advances in technology have accelerated the translation of genetics and genomics into the arena of cancer prevention. This provides unique opportunities to individualize cancer risk prediction so early intervention can either modify risk or allow for early diagnosis thereby potentially decreasing the morbidity and mor...

journal_title：Seminars in oncology

authors： Calzone K,Wattendorf D,Dunn BK

更新日期：2010-08-01 00:00:00

abstract：:Pancreatic cancer is one of the most lethal neoplasms. Incidence in the United States has remained fairly stable over the past 25 years, with about 25,000 cases annually. Almost 100% of cases are fatal. Incidence in the developed world parallels that in the United States. Incidence in undeveloped nations is lower but ...

journal_title：Seminars in oncology

authors： Ahlgren JD

更新日期：1996-04-01 00:00:00

abstract：:A large meta-analysis showed that chemotherapy results in significant prolongation of survival for patients with non-small cell lung cancer (NSCLC). Pemetrexed is a new multitargeted antifolate chemotherapeutic agent that has shown activity in NSCLC and appears to be similar to the third-generation antitumor agents cu...

journal_title：Seminars in oncology

authors： Shepherd FA

更新日期：2002-12-01 00:00:00

abstract：:Recurrent and second primary tumors arising within a previously radiated head and neck volume represent a difficult clinical scenario to manage. For patients who have resectable disease, surgery is the standard treatment. Chemotherapy is the standard for patients with unresectable or metastatic disease but offers no c...

journal_title：Seminars in oncology

authors： Salama JK,Vokes EE

更新日期：2008-06-01 00:00:00

abstract：:Non-Hodgkin's lymphoma (NHL) is composed of a group of lymphoid malignancies that has been increasing in incidence at an annual rate of 4% to 7% over the last 20 years in both the United States and Europe. The reasons for this rise in incidence in NHL are not yet defined but most likely involve environmental exposures...

journal_title：Seminars in oncology

authors： Czuczman MS,Fallon A,Mohr A,Stewart C,Bernstein ZP,McCarthy P,Skipper M,Brown K,Miller K,Wentling D,Klippenstein D,Loud P,Rock MK,Benyunes M,Grillo-López AJ,Bernstein SH

更新日期：2002-02-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options and exceedingly high mortality rates. Currently, cure can only be achieved through resection, however the vast majority of patients present with advanced disease for which upfront surgery is not an option. In...

journal_title：Seminars in oncology

authors： Raufi AG,Manji GA,Chabot JA,Bates SE

更新日期：2019-02-01 00:00:00

abstract：:This article summarizes the likely attenuation properties of RRx-001 in COVID-19 based on its mechanism of action and the putative pathogenesis of the disease, which appears to activate inflammatory, oxidative, and immune cascades with the potential to culminate in acute respiratory distress syndrome, cytokine storm a...

journal_title：Seminars in oncology

authors： Oronsky B,Knox S,Cabrales P,Oronsky A,Reid TR

更新日期：2020-10-01 00:00:00

abstract：:Carcinoma of the bladder is the most prevalent cancer in Egypt and in most African countries. At the National Cancer Institute (NCI), Cairo, it constitutes 30.3% of all cancers. The median age at diagnosis is 46 years, with a male preponderance of 5:1. Whether in Egypt or other African countries such as Sudan, Kenya, ...

journal_title：Seminars in oncology

authors： el-Mawla NG,el-Bolkainy MN,Khaled HM

更新日期：2001-04-01 00:00:00

abstract：:The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with...

journal_title：Seminars in oncology

authors： Capoluongo E,Ellison G,López-Guerrero JA,Penault-Llorca F,Ligtenberg MJL,Banerjee S,Singer C,Friedman E,Markiefka B,Schirmacher P,Büttner R,van Asperen CJ,Ray-Coquard I,Endris V,Kamel-Reid S,Percival N,Bryce J,Röthlisbe

更新日期：2017-06-01 00:00:00

abstract：:Cisplatin has been employed in the treatment of non-small-cell lung cancer (NSCLC) since the late 1970s. Current evidence suggests that it may be the most effective single drug for the treatment of NSCLC patients. The overall response rate as a single agent is 21%, though responses are higher in previously untreated p...

journal_title：Seminars in oncology

authors： Bunn PA Jr

更新日期：1989-08-01 00:00:00

abstract：:Lymphoproliferative disorders are characterized by the abnormal accumulation of aberrant lymphocytes, which frequently interfere with the processes associated with immunologic response and hematopoiesis. Chronic lymphocytic leukemia (CLL) has traditionally been considered indolent, with a prolonged clinical course. Ho...

journal_title：Seminars in oncology

authors： Hillmen P

更新日期：2006-04-01 00:00:00

abstract：:Preclinical models in vitro and in vivo have shown that tumor hypoxia alters the malignant cell phenotype, selecting for p53 mutations, stimulating angiogenesis and metastasis, and markedly reducing the efficacy of both radiotherapy and chemotherapy. Similarly, clinical studies measuring pretreatment tumor oxygen stat...

journal_title：Seminars in oncology

authors： Gandara DR,Lara PN Jr,Goldberg Z,Le QT,Mack PC,Lau DH,Gumerlock PH

更新日期：2002-02-01 00:00:00

abstract：:Based on promising results with 5-FU/FA or 5-FU/IFN-alpha in colorectal cancer, a pilot study was initiated to evaluate the effects of the combination 5-FU/FA/interferon alfa (IFN-alpha) in patients with advanced pancreatic cancer. Patients received 9 million units (MU) IFN-alpha subcutaneously three times a week or 6...

journal_title：Seminars in oncology

authors： Knuth A,Bernhard H,Klein O,Meyer zum Büschenfelde KH

更新日期：1992-04-01 00:00:00

abstract：:Conventional cytogenetic studies have shown that the clinical and biological diversity of acute myeloid leukemia (AML) can be attributed, in part, to distinct chromosome aberrations, several of which are now routinely used for diagnosis, risk stratification, and outcome prediction. Although chromosome banding analysis...

journal_title：Seminars in oncology

authors： Bullinger L,Fröhling S

更新日期：2012-02-01 00:00:00

abstract：:Etoposide phosphate (Etopophos; Bristol-Myers Squibb Company, Princeton, NJ) is a water-soluble prodrug of etoposide that is converted in vivo by endogenous phosphatases to the active drug etoposide. This conversion process is efficient and not saturable in humans at doses between 50 and 1,600 mg/m2. The resultant eto...

journal_title：Seminars in oncology

authors： Budman DR

更新日期：1996-12-01 00:00:00

abstract：:Hepatic metastases are a major cause of morbidity and mortality for patients with colorectal cancer (CRC). The rationale for hepatic arterial chemotherapy has both an anatomical and pharmacological basis. Several randomized clinical studies of fluoropyrimidine showed higher response rates in all trials when the drug w...

journal_title：Seminars in oncology

authors： Kemeny NE,Ron IG

更新日期：1999-10-01 00:00:00

abstract：:Two children with biopsy-proven LCH underwent successful hepatic transplantation for end-stage liver disease. These patients were thought not to have active LCH disease at the time of transplantation, although one had developed a new osteolytic lesion a few months before the operation and the other had suspicious oste...

journal_title：Seminars in oncology

authors： Concepcion W,Esquivel CO,Terry A,Nakazato P,Garcia-Kennedy R,Houssin D,Cox KL

更新日期：1991-02-01 00:00:00

abstract：:Traditionally, medical oncology has focused on the active period of diagnosis, treatment and follow-up of cancer patients, and palliative medicine, the pre-terminal and end-of-life phases. Palliative medicine physicians have particular expertise in communication and symptom control, especially, for example, with pain ...

journal_title：Seminars in oncology

authors： Storey DJ,Fallon MT,Smyth JF

更新日期：2011-06-01 00:00:00